-
2026-06-15 01:20
-
2026-06-14 20:40
-
2026-06-15 01:02
-
2026-06-15 01:01
-
2026-06-15 00:59
-
2026-06-15 00:37
-
2026-06-14 19:02
-
2026-06-15 00:01
-
2026-06-14 23:02
-
2026-06-14 22:57
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24.Post-hoc analysis from the phase 3 SENTR